R

Rajiv Gandhi Cancer Institute and Research Centre | Clinical Research (Dr D.C.Doval)

Research site
(Unclaimed)
Location
D-18, Sector 5, Rohini, New Delhi, Delhi, India

Site insights

Top conditions

Top treatments

Dexamethasone
Selpercatinib
Palbociclib
Topotecan
MeziKD
LY3537982
Irinotecan
Cyclophosphamide
Carfilzomib
Cetuximab

Parent organization

This site is a part of Rajiv Gandhi Cancer Institute and Research Centre

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 6 total trials

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Enrolling
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Carboplatin
Drug: LY3537982

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Placebo
Drug: Selpercatinib

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Dexamethasone

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS)...

Enrolling
Non-Small-Cell Lung Carcinoma
Lung Neoplasms
Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan...

Active, not recruiting
Neuroblastoma
Rhabdomyosarcoma
Drug: Cyclophosphamide
Drug: Temozolomide

Trial sponsors

Pfizer logo
Bristol-Myers Squibb (BMS) logo
Lilly logo
Loxo Oncology logo
Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems